NCT05651815

Graphene Photothermal Adjuvant Therapy for Mild Corona Virus Disease 2019: A Prospective Randomized Controlled Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 270 (estimated)
• Sponsor: Southeast University, China · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This is a future-proof and randomized controlled clinical study on the clinical efficacy of graphene photothermal adjuvant therapy in Corona Virus Disease 2019(COVID-19) patients with mild symptoms. The objective is to examine the effect of graphene photothermal adjuvant therapy on the time line for such Corona Virus Disease 2019 patients to achieve a negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid test result, and their duration of disease. Patients who meet study criteria will be randomized into the Grapheme adjuvant therapy combined with conventional therapy group (treatment group) and the conventional therapy only group (control group). Contrasted to the control groups, the treatment groups will undergo 30-min of graphene adjuvant therapy every day for 7 d.

Detailed description

Following enrollment, patients will be randomized into treatment or control groups. All groups will receive the same conventional therapy. In addition, treatment groups will undergo Graphene adjuvant therapy 30 minutes per day for 7 d. Upon completion of the treatment protocol, specific study endpoints will be compared between the treatment and control groups.

Conditions

• COVID-19

Interventions

Type	Name	Description
DEVICE	Graphene spectrum light wave therapy room	Undergo 30-min of graphene adjuvant therapy every day for 7 d.

Timeline

• Start date: 2022-11-22
• Primary completion: 2022-12-31
• Completion: 2023-06-30
• First posted: 2022-12-15
• Last updated: 2022-12-15

Locations

1 site across 1 country: China